Physician profile
Jai S Perumal
NPI 1710123930
$152,800.26
in general payments reported to CMS, 2019-2025
14 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of Neuromusculoskeletal Medicine, Sports Medicine providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $8,157 · 2021: $5,877 · 2022: $10K · 2023: $30K · 2024: $18K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Travel and Lodging: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $2,991 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,370.50 |
| Travel and Lodging | $20,477.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,374.50 |
| Food and Beverage | $2,991.39 |
| Education | $110.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $35,633.05 | 2019-2025 | Tysabri, Vumerity |
| Emd Serono, INC. | $35,442.26 | 2019-2025 | Mavenclad, Evobrutinib |
| Genzyme Corporation | $29,307.73 | 2019-2021 | |
| Ares Trading Sa | $17,792.82 | 2024 | |
| Merck Healthcare Kgaa | $17,411.82 | 2025 | |
| Genentech USA, INC. | $12,455.43 | 2022-2025 | Ocrevus, Enspryng |
| Tg Therapeutics, INC. | $2,593.14 | 2023-2025 | |
| Horizon Therapeutics Plc | $1,769.25 | 2022-2023 | Uplizna |
| Amgen INC. | $201.91 | 2024-2025 | Uplizna |
| Janssen Pharmaceuticals, INC | $74.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $68.82 | 2019-2025 | |
| Pfizer INC. | $24.86 | 2021 | |
| Medtronic USA, INC. | $24.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jai Perumal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.